Treating Acute Myeloid Leukemia in Patients Presenting with COVID-19

Author Info

Rutger Callens Dieter Stevens Sebastiaan Dhont Elise Peys Ine Moors

Corresponding Author

Ine Moors
Department of Hematology, Ghent University Hospital, Ghent, Belgium

A B S T R A C T

Patients with hematological malignancies are at increased risk for severe COVID-19 with a high mortality rate. In AML, more and more patients are treated on an outpatient basis. This gives rise to two dilemmas in the face of COVID-19. The first one is whether to temporarily interrupt the oral antileukemia treatment and the second one is which patients should be intubated. Here, we describe our institutional approach and the underlying rationale in patients on lower intensity treatments for AML presenting with COVID-19

Article Info

Article Type

Case Report

Publication history

Received: Sat 13, Jun 2020
Accepted: Thu 02, Jul 2020
Published: Sat 18, Jul 2020

Copyright

© 2023 Ine Moors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.07.05